CERENOME, INC. (PSTV) Form 8-K — Aug 14, 2026

$PSTVForm 8-KItems 2.02, 9.01Filed Aug 14, 2026, 4:21 PM ET0001193125-26-352346Original filing

Cerenome, Inc. (Nasdaq: CNSY), rebranded from Plus Therapeutics effective August 3, 2026, reported a second quarter 2026 net loss of $9.0 million, or $1.31 per basic share, a swing from net income of $5.2 million a year earlier that had included a $6.5 million derivative fair-value gain. Operating loss widened to $9.1 million from $1.5 million in the prior-year quarter as R&D rose to $4.3 million and G&A to $5.2 million on the CNSide commercial ramp and REYOBIQ Phase 2 funding, while CPRIT grant revenue fell to $0.4 million from $1.4 million.

Key figures

Eps: -$1.31 per basic share Q2 2026 (vs $0.62 basic in Q2 2025)
Revenue: $0.4 million grant revenue in Q2 2026 (vs $1.4 million in Q2 2025, down ~70%)
Net Income: -$9.0 million Q2 2026 net loss (vs $5.2 million net income in Q2 2025, which included a $6.5 million derivative fair-value gain)
Revenue Yoy: grant revenue down ~70% YoY ($1,390K to $411K)
Total Assets: $14.0 million at June 30, 2026
Cash Position: $8.6 million cash, cash equivalents and investments at June 30, 2026 ($2.4 million cash and equivalents plus $6.2 million investments), level with December 31, 2025
Shares Outstanding: 7310008
Net loss h1 2026: $16.0 million (vs $12.3 million H1 2025)
Ga expense q2 2026: $5.2 million (vs $1.7 million Q2 2025)
Rd expense q2 2026: $4.3 million (vs $1.2 million Q2 2025)
Accumulated deficit: $531.8 million
Stockholders equity: $5.5 million at June 30, 2026
Cnside tests h1 2026: 232
Dod grant respect pbc: $3 million grant
Respect lm enrollment: approximately one-third enrolled as of June 30, 2026, no dose-limiting toxicities
Shares growth h1 2026: ~32% (5,547,034 to 7,310,008)
Cprit grant respect lm: $17.6 million three-year grant
Operating loss h1 2026: $16.2 million
Operating loss q2 2026: $9.1 million (vs $1.5 million Q2 2025)
Covered lives contracted: 150 million commercial payer lives achieved by mid-2026
Operating cash burn h1 2026: $13.4 million net cash used in operating activities
Underwritten offering proceeds h1 2026: $15.0 million
Distribution agreement proceeds h1 2026: $1.9 million

Price after filing

1 day: -0.5%7 days: -17.0%30 days: -37.2%

Close on the filing date to close N calendar days later (from $3.70). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.